Neil Wilkie, Mironid CEO

Mironid reach­es $43.7M to date in Se­ries A ex­ten­sion to fund kid­ney dis­ease treat­ment stud­ies

Mironid has raised a to­tal of £35 mil­lion ($43.7 mil­lion) since its in­cep­tion with the help of a Se­ries A ex­ten­sion raise, set­ting it up to get its lead kid­ney dis­ease pro­gram through IND-en­abling de­vel­op­ment.

The ex­ten­sion saw new Big Phar­ma backer Roche Ven­ture Fund join Mironid’s ex­ist­ing in­vestors, which in­clude Ep­i­darex Cap­i­tal and Sofinno­va Part­ners. The raise fol­lows on from an orig­i­nal Se­ries A round of £4.3 mil­lion that the Scot­tish com­pa­ny com­plet­ed back in June 2016.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.